Table 2. Clinical and radiological characteristics of the study cohort: Univariate analysis of the factors associated with OS.
| Characteristics | N | Value | Univariate | ||
|---|---|---|---|---|---|
| HR (95% CI) | P-value | ||||
| Age (yrs) | < 60/≥ 60 | 158/58 | 53.05 (24–77) | 0.938 (0.638–1.380) | 0.749 |
| Gender | Male/female | 200/16 | - | 1.028 (0.554–1.904) | 0.931 |
| WBC (×109/L) | < 10/≥ 10 | 208/8 | 6.66 (3–13) | 0.458 (0.145–1.442) | 0.182 |
| Neutrophil count (×109/L) | < 7/≥ 7 | 203/13 | 4.26 (1.3–9.9) | 0.750 (0.349–1.612) | 0.461 |
| Lymphocyte count (×109/L) | < 0.8 /≥ 0.8 | 10/206 | 1.61 (0.2–3.9) | 0.508 (0.237–1.088) | 0.081 |
| CRP (mg/L) | < 8/≥ 8 | 98/118 | 21.32 (0.23–269.43) | 2.655 (1.847–3.815) | 0.000 |
| PLT (×109/L) | < 100/≥ 100 | 21/195 | 194.38 (42–490) | 1.161 (0.641–2.103) | 0.622 |
| ALT (U/L) | < 40/≥ 40 | 83/133 | 60.86 (8–669) | 1.281 (0.899–1.826) | 0.171 |
| AST (U/L) | < 45/≥ 45 | 64/152 | 78.12 (10–871) | 2.187 (1.441–3.320) | 0.000 |
| ALB (g/L) | < 35/≥ 35 | 28/188 | 40.11 (28.7–52.9) | 0.617 (0.394–0.969) | 0.036 |
| TBIL (mmol/L) | < 20.5/≥ 20.5 | 169/47 | 16.45 (5–67) | 1.433 (0.966–2.123) | 0.073 |
| IBIL (mmol/L) | < 15/≥ 15 | 199/17 | 9.67 (3–31.4) | 1.285 (0.693–2.382) | 0.427 |
| ALP (U/L) | < 100/≥ 100 | 65/151 | 160.69 (23.4–1962.8) | 1.946 (1.303–2.904) | 0.001 |
| GGT (U/L) | < 50/≥ 50 | 24/192 | 201.42 (12.2–1433.2) | 2.843 (1.389–5.818) | 0.004 |
| AFP (ng/mL) | < 400/≥ 400 | 116/100 | 20430.51 (1–121000) | 2.165 (1.537–3.050) | 0.000 |
| HBV-DNA (IU/mL) | < 100/≥ 100 | 54/162 | 4073691 (0–2.73×108) | 0.967 (0.655–1.427) | 0.866 |
| Tumor diameter (cm) | < 5/≥ 5 | 39/177 | 9.29 (1.2–22.8) | 11.733 (4.334–31.763) | 0.000 |
| Tumor number | single/multiple | 39/177 | - | 1.527 (0.949–2.457) | 0.081 |
| Vascular invasion | absent/present | 133/83 | - | 2.441 (1.737–3.431) | 0.000 |
| NLR | < 1.77/≥ 1.77 | 49/167 | - | 3.178 (1.883–5.364) | 0.000 |
| PLR | < 94.62/≥ 94.62 | 75/141 | - | 1.802 (1.230–2.641) | 0.003 |
| mGPS | 0/1/2 | 112/87/17 | - | 1.977 (1.557–2.510) | 0.000 |
| TNM | I/II/IIIa/IIIb/IV | 23/4/9/98/82 | - | 1.868 (1.537–2.270) | 0.000 |
| PNI | 0/1 | 44/172 | - | 0.525 (0.355–0.777) | 0.001 |
| PI | 0/1/2 | 112/103/1 | - | 2.701 (1.928–3.785) | 0.000 |
| CLIP | 0/1/2/3/4 | 5/51/60/75/25 | - | 1.928 (1.601–2.322) | 0.000 |
| BCLC | A1/A2/A4/B/C | 23/4/9/98/82 | - | 1.607 (1.315–1.964) | 0.000 |
WBC, white blood cell counts; PLT, platelet counts; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALB, albumin; TBIL, total serum bilirubin; IBIL, indirect serum bilirubin; ALP, alkaline phosphatase; GGT, gamma-glutamyl transpeptidase; CRP, C-reactive protein; AFP, alpha-fetoprotein level; HBV-DNA, hepatitis B virus deoxyribonucleic acid; NLR, neutrophil-lymphocyte ratio; PLR, platelet-lymphocyte ratio; mGPS, modified Glasgow Prognostic Score; TNM, tumor-node-metastasis; PNI, prognostic nutritional index; PI, prognostic index; CLIP, Cancer of the Liver Italian Program; BCLC, Barcelona Clinic Liver Cancer; HBV infection, hepatitis B virus infection; HBV-DNA, hepatitis B virus deoxyribonucleic acid; HR, hazard ratio; CI, confidence interval